

Association of the use of hearing aids with the conversion from mild cognitive impairment to dementia and progression of dementia: a longitudinal retrospective study

Magda Bucholc^a, Paula L. McClean^b, Sarah Bauermeister^c, Stephen Todd^d, Xuemei Ding^{a,e}, Qinyong Ye^f, Desheng Wang^g, Wei Huang^g, Liam P. Maguire^a

^a Cognitive Analytics Research Lab, School of Computing, Engineering & Intelligent Systems, Ulster University, BT48 7JL, United Kingdom

^b Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, Ulster University, BT47 6SB, United Kingdom

^c Department of Psychiatry, Warneford Hospital, University of Oxford, OX3 7JX, United Kingdom

^d Altnagelvin Area Hospital, Western Health and Social Care Trust, BT47 6SB, United Kingdom

^e Fujian Provincial Engineering Technology Research Centre for Public Service Big Data Mining and Application, College of Mathematics and Informatics, Fujian Normal University, Fuzhou, Fujian, 350108, China

^f Department of Neurology, Fujian Medical University Union Hospital, Fujian, Fuzhou 350001, China.

^g Department of Otolaryngology, Fujian Medical University Union Hospital, Fujian, Fuzhou 350001, China.

Corresponding author: Magda Bucholc; Cognitive Analytics Research Lab, School of Computing, Engineering & Intelligent Systems, Ulster University, BT48 7JL, United Kingdom. E-mail: m.bucholc@ulster.ac.uk

1 **Abstract**

2 INTRODUCTION: Hearing aid usage has been linked to improvements in cognition,
3 communication, and socialization, but the extent to which it can affect the incidence
4 and progression of dementia is unknown. Such research is vital given the high
5 prevalence of dementia and hearing impairment in older adults, and the fact that
6 both conditions often coexist. In this study, we examined for the first time the effect
7 of the use of hearing aids on the conversion from mild cognitive impairment (MCI) to
8 dementia and progression of dementia.

9 METHODS: We used a large referral-based cohort of 2114 hearing-impaired patients
10 obtained from the National Alzheimer's Coordinating Center. Survival analyses using
11 multivariable Cox proportional hazards regression model and weighted Cox
12 regression model with censored data were performed to assess the effect of hearing
13 aid use on the risk of conversion from MCI to dementia and risk of death in hearing-
14 impaired participants. Disease progression was assessed with CDR® Dementia
15 Staging Instrument Sum of Boxes (CDRSB) scores. Three types of sensitivity
16 analyses were performed to validate the robustness of the results.

17 RESULTS: MCI participants that used hearing aids were at significantly lower risk of
18 developing all-cause dementia compared to those not using hearing aids (hazard
19 ratio [HR] 0.73, 95%CI, 0.61-0.89; false discovery rate [FDR] $P=0.004$). The mean
20 annual rate of change (standard deviation) in CDRSB scores for hearing aid users
21 with MCI was 1.3 (1.45) points and significantly lower than for individuals not wearing
22 hearing aids with a 1.7 (1.95) point increase in CDRSB per year ($P=0.02$). No
23 association between hearing aid use and risk of death was observed. Our findings
24 were robust subject to sensitivity analyses.

25 DISCUSSION: Among hearing-impaired adults, hearing aid use was independently
26 associated with reduced dementia risk. The causality between hearing aid use and
27 incident dementia should be further tested.

28

29 Keywords: dementia; Alzheimer's disease; mild cognitive impairment; MCI; dementia
30 onset; dementia incidence; hearing impairment; hearing loss; hearing aid; risk factor;
31 disease progression; cognitive decline; survival analysis; National Alzheimer's
32 Coordinating Center

33

Highlights

34

35

- High prevalence of dementia and hearing impairment in older adults

36

- Hearing aid (HA) use associated with a lower risk of incident dementia

37

- Slower cognitive decline in users than non-users of HA with mild cognitive

38

impairment

39

- The relationship between hearing impairment and dementia should be further

40

tested

41 **1 Background**

42 The escalating costs and devastating psychological and emotional impact of
43 dementia on affected individuals, their families and caregivers makes the prevention,
44 diagnosis, and treatment of dementia a national public health priority worldwide [1].
45 While the process of drug development to delay the onset of dementia has been
46 slower than initially hoped, there is evidence that behavioural and lifestyle
47 interventions might reduce dementia risk [2-4]. Numerous studies have investigated
48 the effects of physical exercise, healthy diet, and management of medical conditions,
49 such as diabetes and heart disease, on cognitive decline and risk of developing
50 dementia [2,5]. However, there is a paucity of research on hearing impairment and
51 dementia. Such research is vital, given the high prevalence of dementia and hearing
52 impairment in older adults, and the fact that both conditions often coexist.

53 The prevalence of hearing loss is higher among older than younger individuals, with
54 over 70% of adults aged 70 and older having hearing loss in at least 1 ear [6]. In the
55 United States (U.S), mild hearing loss affects 23% of the population over the age of
56 12, with moderate hearing loss more prevalent in those over 80 years [6]. More
57 importantly, approximately 23 million adults with hearing loss in the U.S. do not use
58 hearing aids even though the negative impact of untreated hearing loss has been
59 widely documented [7-9]. The low level of hearing aid adoption is associated with
60 stigma and affordability of hearing aids [8, 15]. Adults with impaired hearing, who do
61 not wear hearing aids demonstrate significantly higher rates of depression, anxiety,
62 and other psychosocial disorders [9,10]. Hearing loss was also associated with
63 increased risk of incident dementia [11-14].

64 Despite the observed relationship between hearing loss and cognition, surprisingly
65 few studies have investigated the association between the use of hearing aids,
66 cognitive decline, and risk for developing dementia [16-17]. One study found little
67 evidence that hearing aids promoted cognitive function but acknowledged that they
68 may be effective in reducing hearing handicap [18]. Other work showed that hearing
69 aid use was associated with better cognition while controlling for confounding by
70 age, sex, general health, and socioeconomic status [19]. A recent randomized pilot
71 study examined the changes in cognition due to treatment of hearing loss, with some
72 promising results for proximal outcomes (perceived hearing handicap, loneliness)
73 that may mediate a relationship between hearing and cognition [10]. Better
74 understanding of the relationship between use of hearing aids cognitive function, and
75 risk of dementia is of utmost importance since it has the potential to significantly
76 impact public health, as hearing aids represent a minimally invasive, cost effective
77 treatment to mitigate the impact of hearing loss on dementia. In fact, it is postulated
78 that up to 9% of dementia cases could be prevented with proper hearing loss
79 management [14]. Slower conversion from MCI to dementia and progression of
80 dementia following hearing aid use could potentially lead to the reduced incidence of
81 dementia and extended preservation of functional independence in people with
82 dementia.

83 In this study, we used data from a large referral-based cohort to examine for the first
84 time the effect of the use of hearing aids on the conversion from Mild Cognitive
85 Impairment (MCI) to dementia and risk of death. We tested if the use of hearing aids
86 is independently associated with a decreased risk of incident all-cause dementia
87 diagnosis for MCI patients and reduced risk of death in individuals with dementia.
88 We also examined if the rate of cognitive decline is slower for hearing aid users

89 when compared to those not using hearing aids in participants with both MCI and
90 dementia at baseline.

91 **2 Methods**

92 *2.1 Participants*

93 We conducted a retrospective analysis of the demographic and clinical data obtained
94 from the National Alzheimer's Coordinating Center (NACC) [20]. The NACC
95 database consists of data from Alzheimer's Disease Research Centers (ADRCs)
96 supported by the National Institute on Aging (NIA) (grant U01AG016976). Details
97 about the NACC consortium, data collection process, and design and
98 implementation of the NACC database have been reported previously [20,21]. The
99 data set used in our longitudinal investigation was the NACC Uniform Data Set
100 (UDS) [21].

101 The analytic sample for this study included 2114 participants (age >50) with hearing
102 impairment who had UDS data in the NACC database available between 2005 and
103 2018 (Fig. 1). All subjects were classified into two groups according to the disease
104 stage. Group 1 included 939 individuals that were diagnosed with MCI at baseline,
105 namely, 497 MCI converters (MCI-c) and 442 MCI non-converters (MCI-nc). Group 2
106 consisted of 1175 participants that were diagnosed with dementia at baseline: 349 of
107 those died during the follow-up. The 829 dementia participants who did not die
108 during the study follow-up were censored at their last clinical evaluation. Note that
109 only patients that clearly progressed from one stage to another were included in the
110 study. In addition, only active participants who continued to return for annual follow-
111 up visits were taken into account and hence, any subject that missed a scheduled
112 appointment (7%) was discarded from the analysis.

113 2.2 *Clinical assessment and diagnosis*

114 The incidence of MCI and all-cause dementia was determined based on the clinical
115 diagnosis made by a single clinician or a consensus panel. The clinical diagnosis
116 took into account patient's medical history, medication use, neuropsychological test
117 performance, and other modifying factors, such as educational and cultural
118 background, and behavioural assessments. In NACC-UDS Version 1 and 2, the
119 procedure of clinical diagnosis of all-cause dementia depended on the diagnostic
120 protocol of the ADRC, but each Center generally adhered to standardized clinical
121 criteria as outlined by the DSM-IV or NINDS-ADRDA guidelines [22,23]. In NACC-
122 UDS Version 3, the coding guidebook criteria for all-cause dementia were modified
123 from the McKhann all-cause dementia criteria (2011) [24]. Diagnoses of MCI were
124 made using the modified Petersen criteria [25].

125 In addition, we used the CDR® Dementia Staging Instrument Sum of Box (CDRSB)
126 scores to assess a decline due to cognitive changes in six functional domains,
127 namely, memory, orientation, judgment and problem solving, community affairs,
128 home and hobbies, and personal care [26]. CDRSB has a total score range from 0 to
129 18 points, with higher scores indicating greater cognitive impairment. CDRSB has
130 been commonly used as a reliable tool for assessing dementia severity [27,28].

131 2.3 *Hearing assessment*

132 The information on presence of hearing loss and use of hearing aids were extracted
133 from the NACC UDS Physical Evaluation form [29]. Information on hearing loss was
134 collected via self-report using a single hearing screening question: "Without a
135 hearing aid(s), is the subject's hearing functionally normal?", which provided possible
136 responses of 'yes' or 'no' [29]. Participants that responded 'yes' were defined as

137 individuals with hearing loss and those that responded 'no' were excluded from the
138 analysis. The determination of severity of hearing loss was not a part of a
139 standardized clinical evaluation given to NACC participants. Although participants
140 were allowed to wear hearing aids during the cognitive assessments, it was not
141 reported to NACC whether a participant was wearing a hearing aid during cognitive
142 testing. Missing codes were however entered when ADRCs had a reason to believe
143 that the test was invalid, including if they were aware that the participant was unable
144 to hear properly. All participants with missing codes were excluded from the analysis.

145 Information on hearing aid use was collected via self-report using a single question:
146 "Does the subject usually wear a hearing aid(s)?", which provided possible
147 responses of 'yes' or 'no' [29]. Participants that responded 'yes' were classified as
148 hearing aid users and those that responded 'no' were classified as non-users of
149 hearing aids. The consistent use (or non-use) of hearing aids was established if the
150 participant answered "yes" or "no" to the above question at every consecutive visit.
151 There was no additional information in the NACC-UDS on the number of
152 hours of daily use of hearing aids, the type of hearing aids used, or the history of
153 hearing aid use before the enrolment in the NACC-UDS.

154 Accordingly, data from individuals identified with impaired hearing at every annual
155 clinical evaluation, that consistently reported non-use or use of hearing aids as well
156 as functionally normal hearing when wearing hearing aids served as the sample for
157 our study. The subject's hearing was characterised as functionally normal with a
158 hearing aid if there was no evidence of reduced ability to do everyday activities such
159 as listening to the radio/television or talking with family/friends [29]. This information
160 was based on self-report. On the other hand, the group of participants excluded from

161 the analysis consisted of subjects without hearing impairment or with inconsistent
162 hearing impairment labelling as indicated by the records from each follow-up visit.
163 Participants with inconsistent records relating to the use or non-use of hearing aids
164 or without functionally normal hearing when wearing a hearing aid were also
165 excluded. The baseline characteristics of participants included and excluded from
166 the study are shown in Table A.1. Among 2114 patients with hearing impairment
167 included in the study, 636 subjects in Group 1 and 710 in Group 2 were classified as
168 using hearing aids.

169 *2.4 Statistical analysis*

170 Baseline summary statistics are presented as proportions for categorical data and
171 means with standard deviations (SD) for continuous variables. Unadjusted analyses
172 for comparison of demographic and clinical features between individuals with hearing
173 impairment that used and did not use hearing aids were performed with the Fisher's
174 exact test and unpaired t test [30]. The average annual rate of change in CDRSB
175 score in individuals using and not using hearing aids was compared by applying
176 Mann Whitney U method [30]. The assumption of normality of CDRSB data was
177 tested using Shapiro-Wilk test [30].

178 A Cox model with censored data was used to study time to incident dementia
179 diagnosis for MCI patients (Group 1) and death for individuals diagnosed with
180 dementia (Group 2) [31]. Censoring was accounted for in the analysis to allow for
181 valid inferences. Ignoring censoring and equating the observed follow-up time of
182 censored subjects with the unobserved total survival time would likely lead to an
183 overestimate of the overall survival probability. The proportional hazards assumption
184 for the Cox regression model fit was tested with the Schoenfeld residuals method

185 and satisfied for Group 1 ($P = 0.7$). The presence of non-proportional hazards was
186 observed in Group 2 ($P = 0.001$), with the proportional hazard assumption violated
187 for age ($P < 0.001$) and CDRSB ($P = 0.007$) variables. Accordingly, we used the Cox
188 proportional hazards regression model to model time to incident dementia for MCI
189 patients (Group 1) and implemented weighted Cox regression accounting for time-
190 varying effects to determine the survival rate of individuals diagnosed with dementia
191 (Group 2) [32]. Weighted Cox regression allowed for providing unbiased estimates of
192 hazard ratios irrespective of proportionality of hazards [32]. Hazard ratios (HR) with
193 95% confidence intervals (95% CI) were calculated for each group by comparing the
194 hazard rates for individuals with hearing impairment who used and did not use
195 hearing aids. All comparisons were adjusted by age, gender, years of education
196 (measured as the number of years of education completed) and CDRSB score to
197 remove their possible confounding effect. The linearity assumption of the relationship
198 between continuous confounding variables (i.e. age, education, CDRSB) and the
199 log-hazard of the time-to-event outcome was tested using the Box-Tidwell approach
200 and satisfied in both groups ($p > 0.05$) [33].

201 For each MCI individual in Group 1 and dementia participant in Group 2, time 'zero'
202 was defined as the date of the baseline evaluation. The diagnosis of MCI in Group 1
203 and dementia in Group 2 referred to the initial event while the endpoint event was
204 considered the conversion to all-cause dementia in Group 1 and the occurrence of
205 death in Group 2 (0 – censored, 1 – uncensored). Survival time was determined by
206 the year. MCI-nc subjects and dementia participants who did not die during the study
207 follow-up were censored at the last clinical assessment.

208 To avoid the inflation of false-positive findings, the Benjamini-Hochberg false
209 discovery rate (FDR) procedure was used to adjust for multiple hypothesis-testing
210 [34]. False discovery-adjusted P values (FDR P) less than 0.05 were considered as
211 statistically significant.

212 2.5 Sensitivity analysis

213 To validate the robustness of the main findings, we performed three different
214 sensitivity analyses: a) propensity score matching to control for measured
215 confounding, b) the analysis for unmeasured confounding to assess the sensitivity of
216 our main conclusions with respect to confounders not included in our study, and c)
217 the inverse probability of treatment weighting method to reduce selection bias within
218 our study population [35,36,37].

219 Propensity scores were generated for hearing aid status using multivariable logistic
220 regression model and adjusting for baseline covariates, including age, gender,
221 education, and CDRSB. The standardized mean difference between two patient
222 groups i.e., patients with and without hearing aids, was then calculated for each
223 covariate and compared before and after the matching process to determine
224 covariate balance between the two groups [34]. A standardized difference of less
225 than 0.1 was considered negligible in the prevalence of a covariate [34].

226 Sensitivity analysis for unmeasured confounding was conducted to measure the
227 potential influence an unmeasured covariate might have on the HR estimates of the
228 association between hearing aid use and a) incident dementia in Group 1 and b)
229 death in Group 2 [36]. We considered prevalence rates for the confounder of 5%,
230 10%, and 20% in the group of hearing aid users and three different values of HR
231 (0.5,2.0,4.0) for the association between the confounder and exposure. We then

232 varied the prevalence of the unmeasured confounder in the group of subjects without
233 hearing aids, from 10% to 30% to determine the extent to which its distribution under
234 these conditions would need to be imbalanced to influence the statistical significance
235 of our findings, i.e., when the upper limit of the 95% CI of HR crosses 1.0.

236 The inverse probability of treatment weighting method was used to attenuate
237 potential selection bias in the sampling and recruitment of NACC participants.
238 Weights were derived from propensity score modelling of the probability of hearing
239 aid use as a function of measured covariates using the Generalized Boosted Model
240 [37]. A multivariable Cox proportional hazards regression model and weighted Cox
241 regression model were then fitted using derived weights to examine the risk of
242 incident dementia and death for hearing aid users and non-users in Group 1 and 2
243 respectively.

244 **3 Results**

245 *3.1 Participant Characteristics*

246 Baseline demographic and clinical characteristics of participants by the hearing aid
247 status are presented in Table 1. Statistically significant differences in the use of
248 hearing aids were found between men and women both in Group 1 ($P = 0.01$) and
249 Group 2 ($P = 0.02$), with higher rates of hearing aid use in males. Hearing aid users
250 with baseline MCI were significantly older than MCI individuals not using hearing
251 aids ($P < 0.001$). Age was comparable for users/non-users of hearing aids in
252 Group 2 ($P = 0.32$). Hearing aid users with dementia had more years of education
253 completed ($P < 0.001$). The CDRSB score was significantly lower in both individuals
254 with baseline MCI and dementia who used hearing aids ($P = 0.01$ and $P < 0.001$
255 respectively).

256 *3.2 Hearing aid status and risk of incident all-cause dementia in MCI participants*

257 During the study follow-up, 497 MCI subjects in Group 1 developed dementia. The
258 median time to incident dementia was 2 years for non-hearing aid users and 4 years
259 for hearing aid users. The 5-year overall survival rate, which is the percentage of
260 participants that did not convert to dementia 5 year after the baseline MCI diagnosis,
261 was 19% for non-hearing aid users and 33% for individuals using hearing aids.

262 In the multivariable Cox proportional hazards regression model, the major risk factor
263 for MCI-to-dementia conversion was the CDRSB score (HR 1.39, 95%CI, 1.30-1.48,
264 FDR $P < 0.001$; Table 2), while a significantly reduced risk of dementia was
265 associated with the use of hearing aids (HR 0.73, 95%CI, 0.61-0.89, FDR $P =$
266 0.004).

267 The observed mean annual (SD) rate of change in CDRSB for non-hearing aid users
268 with MCI was 1.7 (1.95) points per year and significantly higher than the average
269 rate of change for hearing aid users of 1.3 (1.45) CDRSB points per year ($P = 0.02$).

270 *3.3 Hearing aid status and mortality risk in participants with dementia*

271 Group 2 consisted of 1175 individuals diagnosed with dementia at baseline: 349 of
272 those died during the follow-up. The median survival time for dementia participants
273 who did not use hearing aids was 6 years and the 5-year overall survival rate was
274 58%. For hearing aid users, the median survival time was 7 years and the 5-year
275 overall survival rate was 67%.

276 In the weighted Cox regression model accounting for time-varying effects, the
277 relationship between the use of hearing aids and mortality risk was not statistically
278 significant (HR, $\square 0.98$; 95% CI, 0.78-1.24; FDR $P \square = \square 0.89$; Table 3). Higher CDRSB

279 scores were associated with the increased risk of death (HR, 1.08; 95% CI, 1.05-
280 1.11; FDR $P < 0.001$).

281 The average (SD) annual rate of change in CDRSB score of 0.96 (1.02) for hearing
282 aid users with dementia was not significantly different from the 0.94 (1.19) point
283 increase in CDRSB score per year for individuals with dementia not using hearing
284 aids ($P = 0.75$).

285 3.4 Sensitivity analysis

286 The distributions of potential confounders were similar between the hearing aid and
287 non-hearing aid user groups after propensity score matching (standardized
288 difference < 0.1). Again, we found that MCI individuals using hearing aids were at
289 lower risk of developing dementia when compared to non-users of hearing aids (HR
290 0.67, 95%CI, 0.50-0.80, FDR $P = 0.01$) (Table 4). No link between hearing aid use
291 and risk of death was found for individuals with dementia (Table 4).

292 Sensitivity analysis for unmeasured confounding performed for each of two studied
293 groups produced virtually unchanged findings (Table 5). Within Group 1, we
294 observed a lower risk of incident dementia for hearing aid users with the estimated
295 HR for incident dementia in the group of participants with hearing aids below 1 for all
296 considered values of the strength of the confounder-outcome association (HR 0.5,
297 1.5, 2.0, 4.0), and the prevalence of potential confounder in the group of hearing aid
298 users (5%, 10%, 20%) and non-users (10%, 20%, 30%). No association between
299 hearing aid use and risk of death was found in Group 2.

300 The results of the inverse weighted propensity showed the increased risk of
301 dementia for MCI subjects in Group 1 (HR 0.72, 95%CI, 0.60-0.88, FDR $P = 0.003$)

302 and no statistically significant association between hearing aid use and risk of death
303 for dementia participants in Group 2.

304 A lack of improvement in hearing, when a hearing aid is used, may be an indicator of
305 central auditory processing issues rather than a faulty device. As such, we
306 performed additional analysis on a group of hearing aid users that included subjects
307 who still experienced auditory difficulties when wearing a hearing aid (Table A.3). In
308 total, 129 participants in Group 1 and 174 participants in Group 2 were identified as
309 those without functionally normal hearing when wearing a hearing aid. A majority of
310 them, 63% in Group 1 and 68% in Group 2, were males. We observed a lower risk of
311 developing dementia in subjects using hearing aids in Group 1 (HR, \square 0.74; 95% CI,
312 0.61-0.89; FDR P \square = \square 0.003) and no statistically significant relationship between the
313 use of hearing aids and mortality risk in Group 2 (HR, \square 0.99; 95% CI, 0.80-1.23; FDR
314 P \square = \square 0.92).

315 **4 Discussion**

316 Despite the prevalence of auditory impairment in dementia, hearing loss is often not
317 diagnosed and not treated even though hearing loss has been shown to be an
318 independent risk factor for poorer cognitive function [38], depression and loneliness
319 [39], and diminished functional status [39]. Several longitudinal studies indicated that
320 individuals with hearing impairment experience substantially higher risk of incident
321 all-cause dementia [12,40-42]. For instance, the study of Lin et al [12] observed a
322 strong relationship between hearing loss and risk of developing dementia. While the
323 authors observed no association between use of hearing aids and reduced risk of
324 dementia, they found a strong link between degree of hearing loss and dementia
325 incidence [12]. In Ray et al [42], the association between cognitive impairment and

326 degree of hearing loss was also observed but only in individuals who did not use
327 hearing aids.

328 Hypothesized mechanisms explaining the association between hearing impairment
329 and cognitive function included the reallocation of cognitive resources to auditory
330 perceptual processing [43,44,45], cognitive deterioration due to long-term deprivation
331 of auditory input [43,46], a common neurodegenerative process in the aging brain
332 [43], and social isolation caused by both sensory and cognitive loss [45]. In addition,
333 recent findings have suggested that hearing impairment manifested as central
334 auditory dysfunction may be an early marker for dementia [47]. Previous studies
335 concluded that intervention in the form of hearing aids may have a positive effect on
336 cognition [19] and reduce the impact of behavioural and psychological symptoms of
337 dementia [48].

338 In this study, we investigated the relationship between the use of hearing aids with
339 incidence and progression of dementia. Our results clearly suggest that the use of
340 hearing aids is independently associated with a decreased risk of incident all-cause
341 dementia diagnosis for MCI patients. Statistically significant differences in cumulative
342 survival functions by hearing aid status were found in Group 1, with accelerated
343 cognitive decline, as indicated by change in the CDRSB score in the MCI group. The
344 use of hearing aids was not associated with reduced risk of death in people with
345 dementia. Three different sensitivity analyses confirmed the robustness of our
346 findings.

347 So far, hearing aid usage has been linked to improvements in cognition as well as
348 psychological, social, and emotional functioning [13]. Amieva *et al.* [49] showed that
349 non-use of hearing aids was associated with faster cognitive decline as indicated by

350 the accelerated rate of change in Mini Mental State Examination score. Yet, no
351 significant difference in cognitive decline was observed between hearing-impaired
352 subjects using hearing aids and healthy individuals [49]. The recent study of
353 Maharani *et al.* [16] adopted a different approach in examining differences in
354 cognitive outcomes of hearing aid use. To prevent potential residual confounding
355 caused by demographic differences between hearing aid users and non-users, the
356 authors analysed rates of cognitive change before and after hearing aid use in the
357 same individuals. They reported a significantly slower decline in episodic memory
358 scores after patients started to use hearing aids.

359 The potential mechanisms behind the association between the use of hearing aids
360 and cognitive loss, in particular the decreased risk for incident dementia, remain to
361 be determined. Possible explanations include optimized communication and
362 increased social engagement, with resulting lower rates of depression and
363 loneliness, caused by the use of hearing aids and/or changes to the brain associated
364 with the reduced impact of sensory deprivation on brain function [50]. There is also
365 the possibility that facilitated access to auditory information for individuals using
366 hearing aids may result in a reduction in cognitive resources consumed by listening
367 and, hence, lead to improved cognitive ability [50].

368 We acknowledge that biases in our analysis could arise from multiple sources. First,
369 there is selection bias associated with different recruitment strategies implemented
370 by each ADRC. Those enrolling in ADRC cohorts are not random volunteers and
371 therefore, are not representative of a wider population. Their level of education and
372 income is likely above the national average and approximately 50% of subjects have
373 a family history of dementia. These factors may limit generalizability of our findings.

374 Another methodological limitation of our analysis is its reliance on retrospective data.
375 Even though all ADRCs use standard evaluation procedures, there might be some
376 variation in diagnostic criteria between Centers. The lack of use of consistent
377 diagnostic definitions due to the retrospective design of this study can lead to an
378 increased risk of bias due to potential misclassification of the outcome. Furthermore,
379 bias may arise from the degree of accuracy with which subjects have been classified
380 with respect to their exposure status, i.e. hearing status and hearing aid use status.
381 We minimized this bias by considering only participants with a consistent record of
382 hearing impairment and use/non-use of hearing aids. In this way, we could obtain the
383 true effect of hearing aids on incident and progression of dementia. The inclusion of
384 participants with noisy labels could likely result in an over or underestimation of the
385 effect between exposure (hearing aid use) and outcome (incident dementia or
386 death).

387 It is also worth highlighting that the proportion of participants wearing hearing aids in
388 the final groups was considerably higher than the prevalence of hearing aid use in
389 the general population [7]. This potential selection bias might have been introduced
390 into the study at the data-gathering stage (the education level and income of NACC
391 volunteers may not be reflective of the general population) or during the process of
392 identifying the study population. In fact, a large number of participants with dementia
393 were excluded from the analysis due to the lack of consistency in reporting hearing
394 difficulty.

395 Gender, socioeconomic factors and cultural influences all play a role in the use of
396 hearing aids. It may also be the case that unrecorded intrinsic factors that influence
397 use of hearing aids, or lack thereof, play a significant role in the findings presented

398 here. Indeed, severity of cognitive decline may influence acceptance, compliance
399 and correct usage of hearing aids. With incremental changes and decline in
400 cognition, the capacity to comply with the use of hearing aids is likely to significantly
401 diminish [8]. Despite the fact that age, education, gender, and cognitive assessment
402 score were included in the analysis as potential confounders, other unmeasured
403 factors may have impact on the incident and progression of dementia. For instance,
404 hearing aids use in the U.S. is dependent on financial resources as hearing aids are
405 expensive and generally not covered by medical insurance [8]. Other potentially
406 important characteristics not considered in this study due to unavailability of data
407 include type of hearing aid used, hours of daily use, and use of other communicative
408 strategies. Consequently, whether these factors may have a significant effect on time
409 to incident dementia for MCI patients remains unknown and will require further study.

410 Nevertheless, we implemented measures to account for the potential impact of
411 confounding and selection bias in our study. Propensity score matching was applied
412 to control for measured confounding; the analysis for residual confounding was
413 implemented to assess the sensitivity of our main conclusions with respect to
414 confounders not included in our study; and potential selection bias was addressed
415 via the inverse probability of treatment weighting method. Our results remained
416 robust under different assumptions.

417 Finally, this study relies on self-reported hearing loss which is far less reliable than
418 audiometric screening. The use of information on hearing impairment via self-report
419 prevents any adjustment for the effect of degree of hearing loss when investigating
420 the impact of hearing aid usage on incidence and progression of dementia. It is also
421 worth noting that even though ADRCs are anticipated to enter missing codes when

422 they have reason to believe that the cognitive test is invalid, including if they are
423 aware that the participant is unable to hear properly, we cannot exclude the
424 possibility that hearing impairment, rather than cognitive function, impacted the
425 ability to complete tasks on cognitive tests in participants with hearing loss who did
426 not have hearing aids. Since verbal instructions that are used during cognitive testing
427 depend significantly on hearing, hearing loss might have contributed to the
428 overestimation of the level of cognitive impairment in some hearing-impaired
429 individuals.

430 Irrespective of the limitations associated with the present analyses, the fact that
431 significant benefit appears to be derived in delaying conversion of MCI to dementia
432 with hearing aid use warrants further exploration. Properly designed clinical trials will
433 definitively measure the potential benefit of hearing correction in those experiencing
434 hearing loss.

435 **5 Conclusion**

436 Slower conversion from MCI to dementia in individuals using hearing aids suggests
437 that effective identification and treatment of hearing loss may reduce the cumulative
438 incidence of dementia. The competing risk of all-cause mortality and dementia
439 among those with MCI should be examined in future work. One of the findings
440 reviewed above suggested that higher-level cognitive processing involving memory
441 in hearing-impaired individuals might be compromised because of mental resources
442 being reallocated to perception and away from storing information. We believe this
443 hypothesis should be further tested to see if the use of hearing aids can make word
444 identification less effortful and thus, allow for freeing resources for higher-level
445 processing that can in turn result in improvement in cognitive function. Furthermore,

446 more research is needed to better understand the relationship between hearing
447 impairment, changes in cognitive ability, and the role of hearing aids in preventing
448 milder forms of cognitive impairment. Such knowledge may provide new and novel
449 insights into prevention of cognitive decline. Most importantly, the magnitude and
450 causality of the effect of hearing loss treatment on cognitive decline and incident
451 dementia can only be established by conducting a well-designed clinical trial.

452 Public health campaigns are needed to demonstrate the scale and impact of hearing
453 loss and increase awareness regarding effective prevention strategies,
454 consequences of inaction and potential benefits of timely audiological intervention.

455 **Acknowledgements**

456 The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are
457 contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30
458 AG013846 (PI Neil Kowall, MD), P30 AG062428-01 (PI James Leverenz, MD) P50
459 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50
460 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD),
461 P50 AG005146 (PI Marilyn Albert, PhD), P30 AG062421-01 (PI Bradley Hyman, MD,
462 PhD), P30 AG062422-01 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary
463 Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854 (PI
464 Robert Vassar, PhD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI
465 David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129
466 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P30 AG062429-
467 01(PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30
468 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD),
469 P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski,

470 MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui,
471 MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI Suzanne Craft,
472 PhD), P50 AG005136 (PI Thomas Grabowski, MD), P30 AG062715-01 (PI Sanjay
473 Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI
474 Stephen Strittmatter, MD, PhD)

475 **Funding**

476 This work was supported by the Dr George Moore Endowment for Data Science at
477 Ulster University (MB); European Union INTERREG VA Programme (MB, PLM, ST,
478 LPM); Global Challenge Research Fund (MB, XD, QY, DW, WH), Alzheimer's
479 Research UK (MB, SB); European Union Regional Development Fund (PLM);
480 Northern Ireland Public Health Agency (PLM); Dementias Platform UK (DPUK) (SB);
481 Nutricia (ST); Boehringer-Ingelheim (ST); Genomics Medicine Ireland (ST); Vifor
482 Pharma (ST); and Putnam Associates (ST).

483 **Conflict of Interest**

484 The authors declare that they have no competing interests.

485

486 **Ethics approval and consent to participate**

487 The National Alzheimer's Coordinating Center Uniform Data Set (NACC-UDS) is
488 approved by the University of Washington Institutional Review Board and
489 participants provided informed consent at the ADRC where they completed their
490 study visits. The approval was received to use the NACC-UDS data in the present
491 work (application reference: 1026)

References

1. Alzheimer's Association. *Changing the trajectory of Alzheimer's disease: a national imperative*. Alzheimer's Association, USA, 2010.
2. Sabia S, Dugravot A, Dartigues JF, et al. Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study. *BMJ*. 2017;357:j2709.
3. Yaffe K. Modifiable Risk Factors and Prevention of Dementia: What Is the Latest Evidence? *JAMA Intern Med*. 2018;178(2):281–282.
4. Lourida I, Hannon E, Littlejohns TJ, et al. Association of Lifestyle and Genetic Risk With Incidence of Dementia. *JAMA*. 2019;322(5):430–437.
5. Gottesman RF, Albert MS, Alonso A, Coker LH, Coresh J, Davis SM, Deal JA, McKhann GM, Mosley TH, Sharrett AR, Schneider AL. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. *JAMA Neurology*. 2017;74(10):1246-54.
6. Goman AM, Lin FR. Prevalence of hearing loss by severity in the United States. *American journal of public health*. 2016 Oct;106(10):1820-2.
7. Chien W, Lin F.R. Prevalence of hearing-aid use among older adults in the United States. *Arch Intern Med*. 2012;172:292–293.
8. McCormack A, Fortnum H. Why do people fitted with hearing aids not wear them?. *International Journal of Audiology*. 2013;52(5):360-8.
9. Kochkin S, Rogin CM. Quantifying the obvious: The impact of hearing instruments on quality of life. *Hear Rev*. 2000 Jan 1;7(1):6-34.
10. Deal JA, Albert MS, Arnold M, Bangdiwala SI, Chisolm T, Davis S, Eddins A, Glynn NW, Goman AM, Minotti M, Mosley T. A randomized feasibility pilot trial of hearing treatment for reducing cognitive decline: results from the Aging and

- Cognitive Health Evaluation in Elders Pilot Study. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*. 2017;3(3):410-5.
11. Lin FR, Metter EJ, O'Brien RJ, Resnick SM, Zonderman AB, Ferrucci L. Hearing loss and incident dementia. *Archives of neurology*. 2011;68(2):214-20.
 12. Gurgel RK, Ward PD, Schwartz S, Norton MC, Foster NL, Tschanz JT. Relationship of hearing loss and dementia: a prospective, population-based study. *Otol Neurotol*. 2014;35(5):775-81.
 13. Deal JA, Betz J, Yaffe K, et al. Hearing Impairment and Incident Dementia and Cognitive Decline in Older Adults: The Health ABC Study. *J Gerontol A Biol Sci Med Sci*. 2017;72(5):703-709.
 14. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. *The Lancet*. 2017;390(10113):2673-734.109
 15. Yong M, Willink A, McMahon C, McPherson B, Nieman CL, Reed NS, Lin FR. Access to adults' hearing aids: policies and technologies used in eight countries. *Bull World Health Organ*. 2019 Oct 1;97(10):699-710.
 16. Maharani A, Dawes P, Nazroo J, et al. Longitudinal relationship between hearing aid use and cognitive function in older Americans. *Journal of the American Geriatrics Society*. 2018;66(6):1130-6.
 17. Mulrow CD, Tuley MR, Aguilar C. Sustained benefits of hearing aids. *Journal of Speech, Language, and Hearing Research*. 1992;35(6):1402-5.
 18. Dawes P, Cruickshanks KJ, Fischer ME, Klein BE, Klein R, Nondahl DM. Hearing-aid use and long-term health outcomes: Hearing handicap, mental health, social engagement, cognitive function, physical health, and mortality. *International journal of audiology*. 2015 Nov 2;54(11):838-44.

19. Dawes P., Emsley R., Moore D. , Cruickshanks K.J. , Fortnum H . et al. 2015. Hearing loss and cognition: The role of hearing aids, social isolation, and depression. PLOS One.
20. Beekly DL, Ramos EM, van Belle G, et al. The national Alzheimer's coordinating center (NACC) database: an Alzheimer disease database. *Alzheimer Disease & Associated Disorders*. 2004;18(4):270-7.
21. Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: the Uniform Data Set. *Alzheimer Dis Assoc Disord*. 2007;21(3):249–258.
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 1994. Washington.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. *Neurology* 1984, 34(7):939–944
24. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7:263–269.
25. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. *Arch Neurol* 2001; 58:1985–92.
26. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. *Neurology*; 1993;43:2414.

27. Bucholc M, Ding X, Wang H, et al. A practical computerized decision support system for predicting the severity of Alzheimer's disease of an individual. *Expert Systems with Applications*. 2019;130:157-71.
28. Ding X, Bucholc M, Wang H, et al. A hybrid computational approach for efficient Alzheimer's disease classification based on heterogeneous data. *Scientific Reports*. 2018;8(1):9774.
29. University of Washington, NACC Uniform Dataset Guidebook Version 3.0. 2015. Available at:
https://www.alz.washington.edu/NONMEMBER/UDS/DOCS/VER3/UDS3_ivp_guidebook.pdf (accessed: 30.08.2020)
30. Riffenburgh R. *Statistics in Medicine*. 2006. Elsevier
31. Cox DR. Regression models and life-tables. *Journal of the Royal Statistical Society: Series B*. 1972;34(2):187-202.
32. Schemper M, Wakounig S, Heinze G. The estimation of average hazard ratios by weighted Cox regression. *Statistics in medicine*. 2009;28(19):2473-89.
33. Box GE, Tidwell PW. Transformation of the independent variables. *Technometrics*. 1962 Nov 1;4(4):531-50.
34. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society: Series B*. 1995; 57(1): 289–300.
35. Rubin DB. Estimating causal effects from large data sets using propensity scores. *Ann Intern Med* 1997;127 (8, pt 2) 757- 763.
36. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. *Biometrics*. 1998 Sep 1:948-63.

37. Shen C, Li X, Li L, Were MC. Sensitivity analysis for causal inference using inverse probability weighting. *Biometrical journal*. 2011 Sep;53(5):822-37.
38. Alattar AA, Bergstrom J, Laughlin GA, et al. Hearing impairment and cognitive decline in older, community-dwelling adults. *The Journals of Gerontology: Series A*. 2019.
39. Strawbridge WJ, Wallhagen MI, Shema SJ, Kaplan GA. Negative consequences of hearing impairment in old age: a longitudinal analysis. *The Gerontologist*. 2000;40(3):320-6.
40. Michalowsky B, Hoffmann W, Kostev K. Association Between Hearing and Vision Impairment and Risk of Dementia: Results of a Case-Control Study Based on Secondary Data. *Front Aging Neurosci*. 2019; 11.
41. Fritze T, Teipel S, Ovari A, Kilimann I, Witt G, Doblhammer G. Hearing Impairment Affects Dementia Incidence. An Analysis Based on Longitudinal Health Claims Data in Germany. *PloS One*. 2016;11(7): e0156876.
42. Ray, J., Popli, G. and Fell, G., 2018. Association of cognition and age-related hearing impairment in the English Longitudinal Study of Ageing. *JAMA Otolaryngology–Head & Neck Surgery*, 144(10), pp.876-882.
43. Uchida Y, Sugiura S, Nishita Y, Saji N, Sone M, Ueda H. Age-related hearing loss and cognitive decline – The potential mechanisms linking the two. *Auris Nasus Larynx*. 2019;46(1):1-9.
44. Tun PA, McCoy S, Wingfield A. Aging, hearing acuity, and the attentional costs of effortful listening. *Psychology and Aging*. 2009;24(3):761.
45. Wayne RV, Johnsrude IS. A review of causal mechanisms underlying the link between age-related hearing loss and cognitive decline. *Ageing Research Reviews*. 2015;23:154-66.

46. Peelle JE, Troiani V, Grossman M, Wingfield A. Hearing loss in older adults affects neural systems supporting speech comprehension. *Journal of Neuroscience*. 2011;31(35):12638-43.
47. Gates GA, Anderson ML, McCurry SM, Feeney MP, Larson EB. Central auditory dysfunction as a harbinger of Alzheimer dementia. *Archives of Otolaryngology - Head & Neck Surgery*. 2011;137(4):390-5.
48. Kar N. Behavioral and psychological symptoms of dementia and their management. *Indian Journal of Psychiatry*. 2009;51:S77.
49. Amieva H, Ouvrard C, Giulioli C, Meillon C, Rullier L, Dartigues JF. Self-reported hearing loss, hearing aids, and cognitive decline in elderly adults: A 25-year study. *Journal of the American Geriatrics Society*. 2015;63(10):2099-104.
50. Lin FR, Yaffe K, Xia J, et al. Hearing loss and cognitive decline in older adults. *JAMA Internal Medicine*. 2013;173(4):293-9.

Figures

Fig. 1. Selection of participants for study inclusion.




Table 1. Baseline demographic and clinical characteristics of participants by hearing aid status.

Characteristic	Group 1			Group 2		
	Hearing Aid Status		P-value	Hearing Aid Status		P-value
	Used	Not Used		Used	Not Used	
Gender, No. (%)						
Male	411 (64.6)	167 (55.1)	0.01	477 (67.2)	280 (60.2)	0.02
Female	225 (35.4)	136 (44.9)		233 (32.8)	185 (39.8)	
Age, mean (SD), years	79.6 (8.9)	77.3 (8.9)	< 0.001	78.2 (7.8)	77.7 (9.5)	0.32
Education, mean (SD), years ^a	16.4 (7.2)	15.5 (7.6)	0.07	15.4 (3.2)	14.5 (3.8)	< 0.001
CDRSB score, mean (SD)	1.4 (1.1)	1.6 (1.3)	0.01	4.7 (3.0)	6.5 (4.3)	< 0.001

Abbreviation: SD, standard deviation; CDRSB, Clinical Dementia Rating Sum of Boxes

^a measured as the number of years of education completed

Table 2. Risk of incident all-cause dementia by hearing aid status after adjustment for age, gender, race, education, and CDRSB score. Hazard ratios with the 95% confidence interval (95%CI) calculated using Cox proportional hazards regression model. FDR: false discovery rate.

Characteristic	Level	Total	Hazard Ratio (95% CI)	<i>P</i> value	FDR <i>P</i> value
Hearing Aid	No	303			
	Yes	636	0.73 (0.61, 0.89)	0.002	0.004
Gender	Male	578			
	Female	361	1.03 (0.86, 1.24)	0.76	0.93
Age		939	1.01 (0.99, 1.02)	0.31	0.51
Education		939	1.00 (0.99, 1.01)	0.93	0.93
CDRSB score		939	1.39 (1.30, 1.48)	< 0.001	< 0.001

Abbreviation: CDRSB: Clinical Dementia Rating Sum of Boxes; FDR: false discovery rate.

Table 3. Risk of death by hearing aid status for individuals with dementia after adjustment for age, gender, race, education, and CDRSB score. Hazard ratios with the 95% confidence interval (95% CI) calculated using weighted Cox regression model accounting for time-varying effects. FDR: false discovery rate.

Characteristic	Level	Total	Hazard Ratio (95% CI)	<i>P</i> value	FDR <i>P</i> value
Hearing Aid	No	465			
	Yes	710	0.98 (0.78, 1.24)	0.89	0.89
Gender	Male	757			
	Female	418	0.79 (0.63, 0.99)	0.04	0.06
Age		1175	1.02 (1.00, 1.03)	0.02	0.05
Education		1175	1.01 (0.98, 1.05)	0.46	0.57
CDRSB score		1175	1.08 (1.05, 1.11)	< 0.001	< 0.001

Abbreviation: CDRSB: Clinical Dementia Rating Sum of Boxes; FDR: false discovery rate.

Table 4. Risk of incident all-cause dementia (Group 1) and risk of death (Group 2) by hearing aid status in the propensity score matched sample.

Characteristic	Level	Total	Hazard Ratio (95% CI)	P value	FDR P value
<i>Group 1</i>					
Hearing Aid	No	303			
	Yes	303	0.67 (0.50, 0.80)	0.004	0.01
Gender	Male	427			
	Female	179	0.92 (0.71, 1.19)	0.52	0.65
Age		606	1.01 (0.99, 1.02)	0.48	0.65
Education		606	0.99 (0.98, 1.01)	0.9	0.91
CDRSB score		606	1.37 (1.27, 1.50)	< 0.001	< 0.001
<i>Group 2</i>					
Hearing Aid	No	465			
	Yes	465	0.93 (0.69, 1.27)	0.66	0.66
Gender	Male	631			
	Female	299	0.91 (0.70, 1.21)	0.54	0.66
Age		930	1.01 (0.99, 1.03)	0.14	0.35
Education		930	1.02 (0.98, 1.07)	0.28	0.47
CDRSB score		930	1.07 (1.03, 1.10)	< 0.001	0.002

Abbreviation: CDRSB: Clinical Dementia Rating Sum of Boxes; FDR: false discovery rate.

Table 5. Sensitivity analysis for unmeasured confounding

Prevalence of unmeasured confounder (%)		HR adjusted for unmeasured confounder (95% CI) ^a			
Hearing aid used	Hearing aid not used	Unmeasured confounder HR 0.5	Unmeasured confounder HR 1.5	Unmeasured confounder HR 2.0	Unmeasured confounder HR 3.0
<i>Group 1</i>					
5	10	0.75 (0.62,0.91)	0.72 (0.59,0.87)	0.70 (0.58,0.85)	0.67 (0.56,0.82)
	20	0.80 (0.66,0.96)	0.68 (0.57,0.83)	0.64 (0.53,0.78)	0.58 (0.48,0.70)
	30	0.84 (0.70,0.97)	0.65 (0.54,0.79)	0.59 (0.49,0.72)	0.51 (0.42,0.61)
10	10	0.73 (0.61,0.89)	0.73 (0.61,0.89)	0.73 (0.61,0.89)	0.73 (0.61,0.89)
	20	0.78 (0.64,0.94)	0.70 (0.58,0.85)	0.67 (0.56,0.82)	0.63 (0.52,0.76)
	30	0.82 (0.68,0.99)	0.67 (0.55,0.81)	0.62 (0.51,0.75)	0.55 (0.46,0.67)
20	10	0.70 (0.58,0.84)	0.77 (0.64,0.93)	0.80 (0.66,0.97)	0.84 (0.71,0.99)
	20	0.73 (0.61,0.89)	0.73 (0.61,0.89)	0.73 (0.61,0.89)	0.73 (0.61,0.89)
	30	0.78 (0.64,0.94)	0.70 (0.58,0.85)	0.68 (0.56,0.82)	0.64 (0.53,0.78)
<i>Group 2</i>					
5	10	1.03 (0.81,1.31)	0.98 (0.77,1.25)	0.96 (0.75,1.22)	0.92 (0.72,1.17)
	20	1.09 (0.85,1.38)	0.93 (0.73,1.19)	0.88 (0.69,1.12)	0.79 (0.62,1.00)
	30	1.15 (0.90,1.47)	0.89 (0.70,1.14)	0.81 (0.63,1.03)	0.69 (0.54,0.88)
10	10	1.00 (0.79,1.28)	1.00 (0.79,1.28)	1.00 (0.79,1.28)	1.00 (0.79,1.28)
	20	1.06 (0.83,1.35)	0.96 (0.75,1.22)	0.92 (0.72,1.17)	0.86 (0.67,1.10)
	30	1.12 (0.88,1.43)	0.91 (0.72,1.17)	0.85 (0.66,1.08)	0.75 (0.59,0.96)
20	10	0.95 (0.74,1.21)	1.05 (0.82,1.34)	1.09 (0.86,1.39)	1.17 (0.92,1.49)
	20	1.00 (0.79,1.28)	1.00 (0.79,1.28)	1.00 (0.79,1.28)	1.00 (0.79,1.28)
	30	1.06 (0.83,1.35)	0.96 (0.75,1.22)	0.92 (0.73,1.18)	0.88 (0.69,1.12)

Abbreviation: HR, hazard ratio

^aAll models were adjusted for sex, age, education, and CDRSB score

Supplementary material

Table A.1. Baseline demographic and clinical characteristics of participants included and excluded from the study.

	Group 1			Group 2		
	MCI at baseline			Dementia at baseline		
	Excluded	Included		Excluded	Included	
Total	4461	939		8951	1175	
Gender, No. (%)						
Male	2055 (46.1)	578 (61.6)] < 0.001	4259 (47.6)	757 (64.4)] < 0.001
Female	2406 (53.9)	361 (38.4)		4692 (52.4)	418 (35.6)	
Age, mean (SD), years	74.7 (9.0)	78.9 (8.0)	< 0.001	73.4 (9.6)	78.0 (8.5)	< 0.001
Education, mean (SD), years ^a	15.5 (5.9)	16.1 (7.4)	0.03	15.3 (8.3)	15.1 (3.5)	0.12
CDRSB score, mean (SD)	1.4 (1.1)	1.5 (1.2)	0.01	5.7 (3.9)	5.4 (3.7)	0.01

Abbreviation: SD, standard deviation; CDRSB, Clinical Dementia Rating Sum of Boxes

^a measured as the number of years of education completed

Table A.2. Sensitivity analysis based on the inverse probability weighting

Characteristic	Level	Total	Hazard Ratio (95% CI)	P value	FDR P value
<i>Group 1</i>					
Hearing Aid	No	303			
	Yes	636	0.72 (0.60, 0.88)	<0.001	0.003
Gender	Male	578			
	Female	361	0.98 (0.81, 1.20)	0.87	0.87
Age		939	1.01 (0.99, 1.02)	0.31	0.52
Education		939	1.00 (0.98, 1.01)	0.69	0.86
CDRSB score		939	1.35 (1.25, 1.46)	< 0.001	< 0.001
<i>Group 2</i>					
Hearing Aid	No	465			
	Yes	710	0.99 (0.80, 1.23)	0.92	0.92
Gender	Male	757			
	Female	418	0.73 (0.60, 0.91)	0.004	0.01
Age		1175	1.02 (1.00, 1.03)	0.01	0.02
Education		1175	1.01 (0.98, 1.04)	0.49	0.62
CDRSB score		1175	1.08 (1.05, 1.10)	< 0.001	< 0.001

Abbreviation: CDRSB: Clinical Dementia Rating Sum of Boxes; FDR: false discovery rate.

Table A.3. Risk of incident all-cause dementia (Group 1) and risk of death (Group 2) by hearing aid status. The group of hearing aid users consisted of subjects with functionally normal hearing with a device and those that exhibited reduced ability to do everyday activities such as listening to the radio/television or talking with family/friends when wearing a hearing aid

Characteristic	Level	Total	Hazard Ratio (95% CI)	P value	FDR P value
<i>Group 1</i>					
Hearing Aid	No	303			
	Yes	765	0.74 (0.61, 0.89)	0.001	0.003
Gender	Male	659			
	Female	409	1.05 (0.89, 1.25)	0.55	0.69
Age		1068	1.01 (0.99, 1.02)	0.32	0.54
Education		1068	1.00 (0.99, 1.01)	0.82	0.82
CDRSB score		1068	1.40 (1.32, 1.49)	< 0.001	< 0.001
<i>Group 2</i>					
Hearing Aid	No	465			
	Yes	884	0.99 (0.80, 1.23)	0.92	0.89
Gender	Male	876			
	Female	473	0.73 (0.60, 0.91)	0.004	0.01
Age		1349	1.02 (1.00, 1.03)	0.01	0.02
Education		1349	1.01 (0.98, 1.04)	0.49	0.61
CDRSB score		1349	1.07 (1.05, 1.10)	< 0.001	< 0.001

Abbreviation: CDRSB: Clinical Dementia Rating Sum of Boxes; FDR: false discovery rate.

